The Neobiological Revolution is here. Now’s the time to put lessons from the Digital Revolution to use.
Category: biotech/medical – Page 1,766
Say something Eric Klien.
Given the increasing proliferation of AI, I recently carried out a systematic review of AI-driven regulatory gaps. My review sampled the academic literature on AI in the hard and social sciences and found fifty existing or future regulatory gaps caused by this technology’s applications and methods in the United States. Drawing on an adapted version of Lyria Bennett-Moses’s framework, I then characterized each regulatory gap according to one of four categories: novelty, obsolescence, targeting, and uncertainty.
Significantly, of the regulatory gaps identified, only 12 percent represent novel challenges that compel government action through the creation or adaptation of regulation. By contrast, another 20 percent of the gaps are cases in which AI has made or will make regulations obsolete. A quarter of the gaps are problems of targeting, in which regulations are either inappropriately applied to AI or miss cases in which they should be applied. The largest group of regulatory gaps are ones of uncertainty in which a new technology is difficult to classify, causing a lack of clarity about the application of existing regulations.
Novelty. In cases of novel regulatory gaps, a technology creates behavior that requires bespoke government action. Of the identified cases, 12 percent are novel. This includes, for example, the Food and Drug Administration’s (FDA) standard for certifying the safety of high-risk medical devices which is applicable to healthcare algorithms, also called black-box medicine.
Balloon shaping isn’t just for kids anymore. A team of researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) has designed materials that can control and mold a balloon into pre-programmed shapes. The system uses kirigami sheets—thin sheets of material with periodic cuts—embedded into an inflatable device. As the balloon expands, the cuts in the kirigami sheet guide the growth, permitting expansion in some places and constricting it in others. The researchers were able to control the expansion not only globally to make large-scale shapes, but locally to generate small features.
The team also developed an inverse design strategy, an algorithm that finds the optimum design for the kirigami inflatable device that will mimic a target shape upon inflation.
“This work provides a new platform for shape-morphing devices that could support the design of innovative medical tools, actuators and reconfigurable structures,” said Katia Bertoldi, the William and Ami Kuan Danoff Professor of Applied Mechanics at SEAS and senior author of the study.
Rigid electromagnetic actuators have a variety of applications, but their bulky nature limits human-actuator integration or machine-human collaborations. In a new report on Science Advances, Guoyong Mao and a team of scientists in soft matter physics and soft materials at the Johannes Kepler University Linz, Austria, introduced soft electromagnetic actuators (SEMAs) to replace solid metal coils with liquid-metal channels embedded in elastomeric shells. The scientists demonstrated the user-friendly, simple and stretchable construct with fast and durable programmability.
They engineered a SEMA based soft miniature shark and a multi-coil flower with individually controlled petals, as well as a cubic SEMA to perform arbitrary motion sequences. The team adapted a numerical model to support device miniaturization and reduce power consumption with increased mechanical efficiency. The SEMAs are electrically controlled shape-memory systems with applications to empower soft grippers for minimally invasive medical applications. The scientists highlighted the practicality of small size and multi-coil SEMAs for promising applications in medicine, much like in the classic sci-fi movie “Fantastic Voyage,” in which a miniature submarine destroyed a blood clot to save a patient’s life. In reality, Mao et al. aim to develop and deploy SEMA-based advanced microrobots for such futuristic medical applications, including drug delivery and tissue diagnostics with nano-precision.
Antibiotic resistance is on the rise and is recognized by both the CDC1 and the U.S. Military2 as a current – and formidable – global health threat. The U.S Department of Defense (DoD) has long documented the warfighter’s outsized risk of exposure to infectious disease, including the increasing number of multi-drug resistant (MDR) organisms that have challenged military wound care in Iraq and Afghanistan3. Despite this looming crisis, there has been a notable exodus of pharmaceutical companies from the antibiotic space, as well as several high-profile failures of biotechnology companies focused on antibiotic development4. Current therapeutics to combat microbial infections, including MDR microbes and bacterial biothreats, are insufficient to meet the growing need, and existing methods to develop new treatments are too slow and/or costly to combat emerging drug resistance in pathogenic microorganisms.
DARPA’s Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) program aims to utilize a new therapeutic design toolkit and novel strategies/modalities to effectively treat microbial infections. Specifically, HEALR seeks to develop new medical countermeasures (MCMs) by recruiting native cellular machinery to recognize and clear disease-related targets for treating these infections. These advances could result in host-driven degradation or deactivation of pathogen targets, which may not only inhibit but could stop the pathogen in its tracks.
“HEALR presents the opportunity to identify drugs that are safer, more effective, and better address drug resistance and bacterial infections than existing therapeutic modalities,” noted Seth M. Cohen, Ph.D., program manager for the DARPA HEALR program. “By harnessing innate cellular processes, such as those exploited by proteolysis targeting chimeras (PROTACs) and similar approaches, HEALR intends to achieve superior outcomes over existing therapies.”
A bacterial toxin cracks open door to new precision-editing tool for DNA in mitochondria.
Weird enzyme enables researchers to study — and potentially treat — deadly diseases. Feat enables researchers to study — and perhaps treat — deadly diseases.
Child psychiatrist Jon Jureidini and philosopher Leemon McHenry dispute the assumption that all approved drugs and medical devices are safe and effective. They warn that when clinical science is hitched to the pharmaceutical industry’s dash for profits, the scientific method is undermined by marketing spin and cherry-picking of data. They propose a solution inspired by philosopher of science Karl Popper: take drug testing out of the hands of manufacturers.”
It’s time to take trials out of the hands of pharmaceutical makers, argues the latest in a long line of books on corruption and the pharmaceutical industry.
Team members at Adobe have built a new way to use artificial intelligence to automatically personalize a blog for different visitors.
This tool was built as part of the Adobe Sneaks program, where employees can create demos to show off new ideas, which are then showcased (virtually, this year) at the Adobe Summit. While the Sneaks start out as demos, Adobe Experience Cloud Senior Director Steve Hammond told me that 60% of Sneaks make it into a live product.
Hyman Chung, a senior product manager for Adobe Experience Cloud, said that this Sneak was designed for content creators and content marketers who are probably seeing more traffic during the coronavirus pandemic (Adobe says that in April, its own blog saw a 30% month-over-month increase), and who may be looking for ways to increase reader engagement while doing less work.
UK neurologists publish details of mildly affected or recovering Covid-19 patients with serious or potentially fatal brain conditions.